Literature DB >> 31502169

High-Plex Spatially Resolved RNA and Protein Detection Using Digital Spatial Profiling: A Technology Designed for Immuno-oncology Biomarker Discovery and Translational Research.

Joseph M Beechem1.   

Abstract

Digital spatial profiling (DSP) is a nondestructive method for high-plex spatial profiling of proteins and RNA from a wide variety of sample types, including formalin-fixed, paraffin-embedded (FFPE) tissue sections. This method uses small photocleavable oligonucleotide "barcodes" (PC-oligos) covalently attached to in-situ affinity reagents (antibodies and RNA-probes) to provide unlimited multiplexing capability. The photocleavage light is projected onto the tissue slice using two-digital micromirror devices (DMD), containing one-million semiconductor-based micromirrors allowing complete flexibility in the pattern of light utilized for high-plex digital profiling of the tissue. These spatial light-patterns can be automatically configured to profile (1) "tumor-only" cells plus "tumor-microenvironment-only" cells; (2) unique cell types and rare cell features (e.g., macrophages, CD8, CD3, CD45, PD-L1 on macrophages, PD-L1 on tumors, etc.); (3) spatial gradients around cell-features or tumor features (e.g., excluded boundaries); (4) hypothesis-free spatial grids; (5) simple hand-selected geometric areas (e.g., free-hand software-based "drawing" on tissue regions); and (6) or any combination of the above modalities. These DMDs can automatically configure themselves to "align" to the biology presented by each individual tissue section. Advanced validated high-plex panels of proteins (~100-plex) and RNA (up to 20,000-plex) specifically designed for immuno-oncology (IO) have been developed. Immuno-oncology clinical trial samples examined using DSP have already provided key insights into the mechanism of action of combination therapy in melanoma, appearing recently in back-to-back articles published in Nature Medicine. DSP has been developed with knowledge of key immuno-oncology terms (tumor, tumor microenvironment, stroma, etc.) and prevalidated high-plex panels of affinity markers (antibodies and in situ RNA probes) and has the potential to bring the full power of high-plex molecular profiling to spatially resolved studies.

Entities:  

Keywords:  Biomarkers; Digital spatial profiling; High-plex; Imaging; Immuno-oncology; Proteins; RNA

Mesh:

Substances:

Year:  2020        PMID: 31502169     DOI: 10.1007/978-1-4939-9773-2_25

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  24 in total

Review 1.  Precision Medicine in Head and Neck Cancers: Genomic and Preclinical Approaches.

Authors:  Giacomo Miserocchi; Chiara Spadazzi; Sebastiano Calpona; Francesco De Rosa; Alice Usai; Alessandro De Vita; Chiara Liverani; Claudia Cocchi; Silvia Vanni; Chiara Calabrese; Massimo Bassi; Giovanni De Luca; Giuseppe Meccariello; Toni Ibrahim; Marco Schiavone; Laura Mercatali
Journal:  J Pers Med       Date:  2022-05-24

2.  Digital quantification of p16-positive foci in fibrotic interstitial lung disease is associated with a phenotype of idiopathic pulmonary fibrosis with reduced survival.

Authors:  Jonathan Keow; Matthew J Cecchini; Nathashi Jayawardena; Maurizio Zompatori; Mariamma G Joseph; Marco Mura
Journal:  Respir Res       Date:  2022-06-07

3.  Spatially-resolved quantification of proteins in triple negative breast cancers reveals differences in the immune microenvironment associated with prognosis.

Authors:  Rachel L Stewart; Anna P Matynia; Rachel E Factor; Katherine E Varley
Journal:  Sci Rep       Date:  2020-04-20       Impact factor: 4.379

Review 4.  Next Generation Imaging Techniques to Define Immune Topographies in Solid Tumors.

Authors:  Violena Pietrobon; Alessandra Cesano; Francesco Marincola; Jakob Nikolas Kather
Journal:  Front Immunol       Date:  2021-01-27       Impact factor: 7.561

5.  Inter- and intra-tumor heterogeneity of metastatic prostate cancer determined by digital spatial gene expression profiling.

Authors:  Lauren Brady; Michelle Kriner; Ilsa Coleman; Colm Morrissey; Martine Roudier; Lawrence D True; Roman Gulati; Stephen R Plymate; Zoey Zhou; Brian Birditt; Rhonda Meredith; Gary Geiss; Margaret Hoang; Joseph Beechem; Peter S Nelson
Journal:  Nat Commun       Date:  2021-03-03       Impact factor: 14.919

6.  Characterizing the Tumor Immune Microenvironment with Tyramide-Based Multiplex Immunofluorescence.

Authors:  Hidetoshi Mori; Jennifer Bolen; Louis Schuetter; Pierre Massion; Clifford C Hoyt; Scott VandenBerg; Laura Esserman; Alexander D Borowsky; Michael J Campbell
Journal:  J Mammary Gland Biol Neoplasia       Date:  2021-02-15       Impact factor: 2.673

7.  From imaging a single cell to implementing precision medicine: an exciting new era.

Authors:  Loukia G Karacosta
Journal:  Emerg Top Life Sci       Date:  2021-12-21

8.  Postmortem high-dimensional immune profiling of severe COVID-19 patients reveals distinct patterns of immunosuppression and immunoactivation.

Authors:  Haibo Wu; Peiqi He; Yong Ren; Shiqi Xiao; Wei Wang; Zhenbang Liu; Heng Li; Zhe Wang; Dingyu Zhang; Jun Cai; Xiangdong Zhou; Dongpo Jiang; Xiaochun Fei; Lei Zhao; Heng Zhang; Zhenhua Liu; Rong Chen; Weiqing Li; Chaofu Wang; Shuyang Zhang; Jiwei Qin; Björn Nashan; Cheng Sun
Journal:  Nat Commun       Date:  2022-01-12       Impact factor: 14.919

9.  Path to Clonal Theranostics in Luminal Breast Cancers.

Authors:  Nawale Hajjaji; Soulaimane Aboulouard; Tristan Cardon; Delphine Bertin; Yves-Marie Robin; Isabelle Fournier; Michel Salzet
Journal:  Front Oncol       Date:  2022-01-13       Impact factor: 6.244

10.  Dissecting the immune landscape of tumor draining lymph nodes in melanoma with high-plex spatially resolved protein detection.

Authors:  Georgia M Beasley; Aaron D Therien; Eda K Holl; Rami Al-Rohil; Maria Angelica Selim; Nellie E Farrow; Liuliu Pan; Premi Haynes; Yan Liang; Douglas S Tyler; Brent A Hanks; Smita K Nair
Journal:  Cancer Immunol Immunother       Date:  2020-08-19       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.